Published in Trends Parasitol on February 11, 2008
A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med (2009) 12.82
Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J (2009) 2.70
Substandard and counterfeit medicines: a systematic review of the literature. BMJ Open (2013) 2.30
Mobile phone text messaging: tool for malaria control in Africa. PLoS Med (2012) 1.88
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med (2013) 1.64
Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health (2015) 1.54
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52
Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children. Clin Infect Dis (2016) 1.46
Efficacy and safety of artemether-lumefantrine in the treatment of acute, uncomplicated Plasmodium falciparum malaria: a pooled analysis. Am J Trop Med Hyg (2011) 1.44
Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol (2008) 1.39
Pharmacokinetic and pharmacodynamic considerations in antimalarial dose optimization. Antimicrob Agents Chemother (2013) 1.21
Evolutionary biology and the avoidance of antimicrobial resistance. Evol Appl (2009) 1.16
New medicines for tropical diseases in pregnancy: catch-22. PLoS Med (2008) 1.16
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. Antimicrob Agents Chemother (2011) 1.15
Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity. Biochemistry (2009) 1.13
Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants. J Infect Dis (2013) 1.07
Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure. Antimicrob Agents Chemother (2011) 1.04
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J (2011) 1.02
Challenges of drug-resistant malaria. Parasite (2014) 1.02
Amodiaquine dosage and tolerability for intermittent preventive treatment to prevent malaria in children. Antimicrob Agents Chemother (2010) 1.00
Mathematical models for a new era of malaria eradication. PLoS Med (2008) 0.98
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J (2013) 0.96
Cluster randomized trial of text message reminders to retail staff in tanzanian drug shops dispensing artemether-lumefantrine: effect on dispenser knowledge and patient adherence. Am J Trop Med Hyg (2014) 0.94
Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria. PLoS Med (2008) 0.94
Malaria in infants below six months of age: retrospective surveillance of hospital admission records in Blantyre, Malawi. Malar J (2009) 0.94
Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res (2009) 0.94
Assessment of Malawian mothers' malaria knowledge, healthcare preferences and timeliness of seeking fever treatments for children under five. Int J Environ Res Public Health (2015) 0.93
Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children. Am J Trop Med Hyg (2014) 0.93
Substandard/counterfeit antimicrobial drugs. Clin Microbiol Rev (2015) 0.91
Cytostatic versus cytocidal activities of chloroquine analogues and inhibition of hemozoin crystal growth. Antimicrob Agents Chemother (2012) 0.91
Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether. Antimicrob Agents Chemother (2011) 0.88
Towards optimal design of anti-malarial pharmacokinetic studies. Malar J (2009) 0.85
Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model. Antimicrob Agents Chemother (2014) 0.83
Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics (2009) 0.83
Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. Int J Parasitol Drugs Drug Resist (2012) 0.83
Measuring Patient Adherence to Malaria Treatment: A Comparison of Results from Self-Report and a Customised Electronic Monitoring Device. PLoS One (2015) 0.80
Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria. Clin Pharmacol Ther (2015) 0.80
Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy? Malar J (2015) 0.80
Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges. Br J Clin Pharmacol (2015) 0.79
Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study. PLoS One (2016) 0.79
Artemisinin-based combination therapy in the treatment of uncomplicated malaria: review of recent regulatory experience at the European Medicines Agency. Int Health (2015) 0.77
The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum. Malar J (2012) 0.77
Artemether-Lumefantrine Pharmacokinetics and Clinical Response Are Minimally Altered in Pregnant Ugandan Women Treated for Uncomplicated Falciparum Malaria. Antimicrob Agents Chemother (2015) 0.77
Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs. AAPS J (2014) 0.77
Development of drugs for severe malaria in children. Int Health (2016) 0.76
Antimalarial mass drug administration: ethical considerations. Int Health (2016) 0.76
Efficacy of artemether-lumefantrine in relation to drug exposure in children with and without severe acute malnutrition: an open comparative intervention study in Mali and Niger. BMC Med (2016) 0.75
Evaluation of the paediatric dose of chloroquine in the treatment of Plasmodium vivax malaria. Malar J (2016) 0.75
Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. J Infect Dis (2016) 0.75
Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children. Open Forum Infect Dis (2016) 0.75
Mathematical Modelling to Guide Drug Development for Malaria Elimination. Trends Parasitol (2016) 0.75
Estimation of the in-vivo minimum inhibitory concentration of cipargamin in uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother (2016) 0.75
Validation and pharmacokinetic application of a high-performance liquid chromatographic technique for determining the concentrations of amodiaquine and its metabolite in plasma of patients treated with oral fixed-dose amodiaquine-artesunate combination in areas of malaria endemicity. Antimicrob Agents Chemother (2015) 0.75
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Antimicrob Agents Chemother (2017) 0.75
Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2009) 33.25
Typhoid fever. N Engl J Med (2002) 12.96
Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med (2014) 11.87
Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet (2012) 11.82
Vivax malaria: neglected and not benign. Am J Trop Med Hyg (2007) 10.16
Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med (2004) 10.14
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med (2005) 8.36
Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis (2012) 6.94
Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol (2006) 6.34
A major genome region underlying artemisinin resistance in malaria. Science (2012) 6.25
Mixed-species malaria infections in humans. Trends Parasitol (2004) 6.01
Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One (2009) 5.81
Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J (2011) 5.65
Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet (2013) 5.22
Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. PLoS Med (2005) 4.65
Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg (2007) 4.58
Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A (2010) 4.50
Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med (2005) 4.47
Manslaughter by fake artesunate in Asia--will Africa be next? PLoS Med (2006) 4.46
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malar J (2008) 4.33
In vivo parasitological measures of artemisinin susceptibility. J Infect Dis (2010) 4.25
The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J (2009) 4.25
Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis (2006) 4.14
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A (2012) 4.10
Early origin and recent expansion of Plasmodium falciparum. Science (2003) 4.07
Counterfeit anti-infective drugs. Lancet Infect Dis (2006) 3.91
Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet (2006) 3.90
Rickettsial infections and fever, Vientiane, Laos. Emerg Infect Dis (2006) 3.87
High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis (2010) 3.81
Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004) 3.72
A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol Biol Evol (2003) 3.67
Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis (2002) 3.46
Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis (2010) 3.21
The global threat of counterfeit drugs: why industry and governments must communicate the dangers. PLoS Med (2005) 3.15
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malar J (2012) 3.13
How much fat is necessary to optimize lumefantrine oral bioavailability? Trop Med Int Health (2007) 3.13
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect Dis (2010) 3.08
The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis (2008) 3.05
Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis (2009) 3.05
How do patients use antimalarial drugs? A review of the evidence. Trop Med Int Health (2005) 2.95
Spurious amplification of a Plasmodium vivax small-subunit RNA gene by use of primers currently used to detect P. knowlesi. J Clin Microbiol (2009) 2.85
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Antimalarial drug toxicity: a review. Drug Saf (2004) 2.76
Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother (2010) 2.68
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis (2007) 2.65
Counterfeit artesunate antimalarials in southeast Asia. Lancet (2003) 2.59
Editorial: clinical trials in tropical diseases: a politically incorrect view. Trop Med Int Health (2006) 2.59
Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Trop (2004) 2.58
Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infect Dis (2012) 2.58
Short communication: An assessment of the use of malaria rapid tests by village health volunteers in rural Laos. Trop Med Int Health (2004) 2.56
Murder by fake drugs. BMJ (2002) 2.54
Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics (2011) 2.53
Artemisinin-based combinations. Curr Opin Infect Dis (2005) 2.51
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. Int J Parasitol (2007) 2.41
Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Trans R Soc Trop Med Hyg (2005) 2.38
The influence of HIV infection on clinical presentation, response to treatment, and outcome in adults with Tuberculous meningitis. J Infect Dis (2005) 2.38
Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med (2009) 2.36
Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol (2006) 2.36
Nonrandom distribution of Burkholderia pseudomallei clones in relation to geographical location and virulence. J Clin Microbiol (2006) 2.34
The transcriptome of Plasmodium vivax reveals divergence and diversity of transcriptional regulation in malaria parasites. Proc Natl Acad Sci U S A (2008) 2.33
Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob Agents Chemother (2002) 2.32
The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg (2004) 2.32
Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis. J Infect Dis (2005) 2.29
Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother (2003) 2.26
Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24
The World Bank: false financial and statistical accounts and medical malpractice in malaria treatment. Lancet (2006) 2.22
The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci (2002) 2.20
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J (2006) 2.19
Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther (2006) 2.18
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother (2004) 2.17
Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis (2011) 2.16
Biological relevance of colony morphology and phenotypic switching by Burkholderia pseudomallei. J Bacteriol (2006) 2.16
An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis (2004) 2.16
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J (2005) 2.15
Risk factors for recurrent melioidosis in northeast Thailand. Clin Infect Dis (2006) 2.14
Spatial and temporal epidemiology of clinical malaria in Cambodia 2004-2013. Malar J (2014) 2.12
Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. J Antimicrob Chemother (2005) 2.08
Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One (2009) 2.05
Causes of community-acquired bacteremia and patterns of antimicrobial resistance in Vientiane, Laos. Am J Trop Med Hyg (2006) 2.04
A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg (2004) 2.02
The first Plasmodium vivax relapses of life are usually genetically homologous. J Infect Dis (2011) 2.02
Short report: a rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis. Am J Trop Med Hyg (2002) 2.01
IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol (2005) 2.00
Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol (2005) 1.99
Relative contributions of macrovascular and microvascular dysfunction to disease severity in falciparum malaria. J Infect Dis (2012) 1.99
Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. J Infect Dis (2008) 1.96